Contact Information: Contact Information US Investors: Andrea Costa The Global Consulting Group (646) 284-9461 acosta@hfgcg.com Company: Mark Diamond Managing Director +61 3 9827 8999
Antisense Therapeutics to Present at Sachs Associates 7th Annual North America Forum for Investing and Partnering in Biotech
| Source: Antisense Therapeutics Limited
MELBOURNE, AUSTRALIA--(Marketwire - February 22, 2008) - Antisense Therapeutics Limited (ASX : ANP ) today announced that the Company is scheduled to present at Sachs
Associates 7th Annual North America Forum for Investing and Partnering in
Biotech taking place on February 25-26 in Boston at the Fairmont Copley
Plaza.
Mark Diamond, Antisense Therapeutics Chief Executive Officer, will give a
presentation on February 25 at 11:30 a.m. ET on the Company and its lead
compound, ATL1102, which is currently in Phase IIa clinical trials as a
treatment for multiple sclerosis (MS). The presentation will be followed
by a question and answer session and a live webcast may be accessed at
http://www.investorcalendar.com/CEPage.asp?ID=126176.
A replay of the presentation will be archived for 12 months after the
conference, at the same website link. For more information about Sachs
Associates 7th Annual North America Forum for Investing and Partnering in
Biotech, please visit the Sachs Associates website at www.sachsforum.com.
Antisense management will be available for meetings in Boston on February
25-26, and in New York on February 27-28.
The Company's current Phase IIa trial is a study in 77 patients to assess
the safety and efficacy of ATL1102 as a treatment for relapsing remitting
MS. Results are anticipated by mid-year 2008.
ATL1102 is a second-generation antisense inhibitor of CD49d, a subunit of
VLA-4 (Very Late Antigen-4). It is believed that the inhibition of VLA-4
prevents white blood cells from entering sites of inflammation, thereby
halting the progression of inflammatory diseases such as MS. VLA-4 is a
clinically validated target in the treatment of MS. Antisense inhibition
of VLA-4 has demonstrated positive effects in an animal model of MS and the
data has been published -- Myers et al., J Neuroimmunol 160, 12-24 (2005).
About Antisense Therapeutics Limited
Antisense Therapeutics Limited (ASX : ANP ) is an Australian publicly listed
biopharmaceutical drug discovery and development company. Its mission is
to create, develop and commercialize novel antisense pharmaceuticals for
large unmet markets. Antisense Therapeutics' strategic technology partner
is Isis Pharmaceuticals Inc.
ANP has two drugs in development and two drugs in pre-clinical research.
Its lead drug, ATL1102, is in the advanced stages of a Phase IIa trial as a
potential treatment of multiple sclerosis.
Website: www.antisense.com.au